Limited coverage criteria – leuprolide acetate
Last updated on May 6, 2026
Return to Special Authority drug list
Generic name |
leuprolide acetate |
|---|---|
Strength & form |
3.75 mg, 7.5 mg, 11.25 mg, 22.5 mg syringe kit |
Special Authority criteria |
Approval period |
|---|---|
| Diagnosis of precocious puberty |
Initial: 1 year Renewal: 1 year |
|
Diagnosis of endometriosis |
Initial: 6 months Renewal: 6 months |
|
Diagnosis indicating need to reduce sexual drive |
Indefinite |
Practitioner exemptions
- Pediatric endocrinologists are not required to submit a Special Authority request for coverage
Special notes
- For patients with a diagnosis indicating need to reduce sexual drive, PharmaCare coverage for Lupron is available under Plan G
- For patients with a diagnosis of precocious puberty or endometriosis, PharmaCare Plan G coverage is not available for Lupron
- For any cancer-related condition, please contact the BC Cancer Agency at (604) 877-6098 ext. 4610